Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
|Videos|October 21, 2020
Video Series test
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pharma Leaders Weigh in On AI's Measurable Results In 2026
2
Manufacturing Intelligence: How AI Poisoning Hides in Plain Sight
3
Ask the Expert: Choosing Ingredient Suppliers
4
Why BMS, Roche, and LGM Pharma Outsourced Key Capabilities
5